Skip to main content
Year archive

Cantargia — 2019 filings

All 61 regulatory filings released by Cantargia (CANTA) in 2019, sourced directly from the official regulator.

61 Filings
2019 Period
2019 filings (61)
Filing Released Lang
Cantargia väljer CAN10 som utvecklingsprojekt inom systemisk skleros och myokardit
Regulatory Filings
2019-12-09 Swedish
Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis
Regulatory Filings
2019-12-09 English
Cantargia reports positive interim data from ongoing phase IIa combination study with antibody CAN04
Earnings Release FY 2019
2019-12-02 English
Cantargia rapporterar positiva interimsdata från pågående fas IIa-kombinationsstudien med antikroppen CAN04
Regulatory Filings
2019-12-02 Swedish
Cantargia AB: Nomination Committee appointed ahead of 2020 Annual General Meeting
AGM Information
2019-11-25 English
Cantargia AB: Valberedning utsedd inför årsstämman 2020
Board/Management Information
2019-11-25 Swedish
Cantargia presents novel preclinical data on antibody CAN04 at PEGS Europe conference
Regulatory Filings
2019-11-18 English
Cantargia presenterar nya prekliniska data runt antikroppen CAN04 på PEGS Europe konferensen
Earnings Release FY 2019
2019-11-18 Swedish
Cantargia avancerar utvecklingen av antikroppen CAN04 efter positivt pre-IND möte
Regulatory Filings
2019-11-15 Swedish
Cantargia advance antibody CAN04 development after positive pre-IND meeting
Regulatory Filings
2019-11-15 English
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-15 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-15 English
Cantargia reports filing of opposition against Cantargia patent in Europe
Legal Proceedings Report
2019-10-10 English
Cantargia meddelar att en opposition lämnats in mot ett av Cantargias patent i Europa
Legal Proceedings Report
2019-10-10 Swedish
Cantargia ansöker om pre-IND möte för CAN04 med FDA
Regulatory Filings
2019-09-04 Swedish
Cantargia submits request for pre-IND meeting on CAN04 with US FDA
Regulatory Filings
2019-09-04 English
Cantargia announce positive preclinical data on CAN04 in bladder cancer
Regulatory Filings
2019-08-23 English
Cantargia meddelar positiva prekliniska data för CAN04 i urinblåsecancer
Regulatory Filings
2019-08-23 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-08-22 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H2 2019
2019-08-22 English
Cantargia meddelar att CAN04 monoterapi-armen i den pågående fas IIa kliniska prövningen är fullrekryterad
Legal Proceedings Report
2019-07-04 Swedish
Cantargia announce full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial
Regulatory Filings
2019-07-04 English
Cantargias styrelseledamot och grundare Thoas Fioretos säljer 250 000 Cantargia-aktier till institutionell investerare
Director's Dealing
2019-06-13 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification
2019-06-11 English
Cantargia: presentation of phase I clinical data on antibody CAN04 at ASCO
Regulatory Filings
2019-06-02 English
Cantargia: presentation på ASCO av fas I kliniska data på antikroppen CAN04
Earnings Release FY 2019
2019-06-02 Swedish
Annual General Meeting in Cantargia AB (publ)
AGM Information
2019-05-27 English
Årsstämma i Cantargia AB (publ)
AGM Information
2019-05-27 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-27 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-27 English
Cantargia: sammanfattning publicerad inför den muntliga presentationen av fas I data för antikroppen CAN04 på ASCO
Regulatory Filings
2019-05-15 Swedish
Cantargia: abstract published for the oral presentation of antibody CAN04 phase I data at ASCO
Regulatory Filings
2019-05-15 English
Cantargia announces new pre-clinical results showing consistent positive effects of the antibody CAN04 when combined with platinum-based chemotherapies
Environmental & Social Information
2019-05-14 English
Cantargia meddelar nya prekliniska resultat som genomgående visar positiva effekter när antikroppen CAN04 kombineras med platinumbaserade cellgifter
Earnings Release FY 2019
2019-05-14 Swedish
Cantargia signs agreement with Patheon Biologics B.V. for production of antibody CAN04
Regulatory Filings
2019-05-13 English
Cantargia ingår avtal med Patheon Biologics B.V. för produktion av antikroppen CAN04
Regulatory Filings
2019-05-13 Swedish
Annual Report 2018
Annual Report FY 2018
2019-04-30 Swedish
Nytt antal aktier och röster i Cantargia
Share Issue/Capital Change
2019-04-30 Swedish
New number of shares and votes in Cantargia
Declaration of Voting Results & Voting Rights Announcements
2019-04-30 English
Notice of Annual General Meeting in Cantargia AB (publ)
AGM Information
2019-04-26 English
Kallelse till årsstämma i Cantargia AB (publ)
AGM Information
2019-04-26 Swedish
Cantargia phase I clinical results on the antibody CAN04 selected for oral presentation at ASCO
Regulatory Filings
2019-04-18 English
Cantargias fas I kliniska resultat för antikroppen CAN04 utvalda för muntlig presentation på ASCO
Regulatory Filings
2019-04-18 Swedish
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-04-05 English
Cantargia makes a directed share issue of approximately SEK 106 million for increased investments in the clinical development of CAN04
Capital/Financing Update
2019-03-21 English
Cantargia genomför riktad nyemission om cirka 106 miljoner kronor för utökad klinisk satsning på CAN04
Capital/Financing Update
2019-03-21 Swedish
Earnings Release 2018
Earnings Release Q4 2018
2019-02-27 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report FY 2018
2019-02-27 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-21 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-20 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-02-19 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-15 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-13 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-12 English
Cantargia: första patienten behandlad med antikroppen CAN04 i fas IIa-delen av CANFOUR-studien
Legal Proceedings Report
2019-01-25 Swedish
Cantargia: first patient treated with antibody CAN04 in the phase IIa part of CANFOUR trial
Regulatory Filings
2019-01-25 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-23 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-21 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-15 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-01-14 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-04 English